The authors report their experience with 20 patients subjected to metabolic radiotherapy with Sr-89 for palliation of bone metastases in advanced prostatic cancer. Sr-89 is an effective symptomatic treatment, generally well tolerated, with minimal adverse effects.
BoringC.C., SquiresT.S., TongT.: Cancer statistics 1991. Cancer J. Clin., 41: 19–36, 1991.
2.
CrowfordE.D., KozlowskiJ.M., DebruyneF.M.J., FairW.R., LogothetisC.J., BalmerC., RobinsonR., PorterA.T., KirkD.: The use of Strontium-89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer. Urology, 44: 481–485, 1994.
3.
BlakeG.M., ZivanovicM.A., Mc EwanA.J., AckeryD.M.: Sr-89 therapy: strontium kinetics in desiminated carcinoma of the prostate. Eur. J. Nucl. Med., 12: 447–454, 1986.
4.
RobinsonR.G., SpicerJ.A., PrestonD.F., WegstA.V., MartinN.C.: Treatment of metastatic bone pain with Strontium-89. Nucl. Med. Biol., 14: 219–222, 1987.
5.
Calais daSilva F., ReisE., CostaT., DenisL.: Quality of life in patients with prostatic cancer. Cancer, 71: 1138–1142, 1993.
6.
AckeryD.M., YardleyJ.: Radionuclide-targeted therapy for the management of metastatic bone pain. Sem. Oncol., 20 (suppl. 2): 27–31, 1993.
